Deal watch: GSK acquires rights to Valeant's anti-epileptic drug.
D000927:Anticonvulsants / Q000191:economics* / Q000627:therapeutic use; D002219:Carbamates / Q000191:economics* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003132:Commerce / Q000331:legislation & jurisprudence*; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence; D004827:Epilepsy / Q000188:drug therapy; D007880:Legislation, Drug; D010655:Phenylenediamines / Q000191:economics* / Q000627:therapeutic use
D000927:Anticonvulsants; D002219:Carbamates; D010655:Phenylenediamines; C101866:ezogabine